logo BDSP

Base documentaire

  1. Antibiotic strategies for developing countries : Experience with acute respiratory tract infections in Pakistan.

    Article, Communication - En anglais

    International Conference on acute respiratory infections. Canberra, AUS, 1997/07/07.

    The Pakistan program for control of acute respiratory tract infections (ARIs) adopted the standard ARI-case-management strategy of the World Health Organization and recommended co-trimoxazole for the management of nonsevere pneumonia.

    Reports in that country of high in vitro antimicrobial resistance of Streptococcus pneumoniae and Haemophilus influenzae to co-trimoxazole prompted the program to reevaluate its treatment policy.

    Two community-based studies during 1991-1993 showed in vivo efficacy of co-trimoxazole in 92% and 91% of children with nonsevere pneumonia.

    A third double-blind trial showed co-trimoxazole and oral amoxicillin to be equally effective in vivo in cases of nonsevere pneumonia, despite high in vitro resistance.

    Country-wide surveillance from 1991 to 1994 revealed 78.3% - 79.9% in vitro resistance to co-trimoxazole among S. pneumoniae isolates and 59.5% - 61.0% among H. influenzae isolates.

    Co-trimoxazole is still recommended by the Pakistan ARI control program.

    The fact that amoxicillin is three times more expensive and must be administered more frequently is a big impediment to recommending it as a first-line drug for nonsevere pneumonia.

    Mots-clés Pascal : Infection, Aigu, Programme sanitaire, Prévention, Lutte sanitaire, Recommandation, Sulfaméthoxazole, Pays en développement, Protocole thérapeutique, Pneumonie, Pakistan, Asie, Homme, Triméthoprime, Surveillance sanitaire, Résistance, Microorganisme, Chimiothérapie, Traitement, Sulfamides, Sulfonamide, Appareil respiratoire pathologie, Poumon pathologie

    Mots-clés Pascal anglais : Infection, Acute, Sanitary program, Prevention, Sanitary control, Recommendation, Sulfamethoxazole, Developing countries, Therapeutic protocol, Pneumonia, Pakistan, Asia, Human, Trimethoprim, Sanitary surveillance, Resistance, Microorganism, Chemotherapy, Treatment, Sulfanilamide derivatives, Sulfonamide, Respiratory disease, Lung disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0156568

    Code Inist : 002B02S02. Création : 16/11/1999.